IRIS Institutional Research Information System - OPENBS Open Archive UniBS

FRANCESCHINI, Franco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.999
EU - Europa 10.246
AS - Asia 8.654
SA - Sud America 1.870
AF - Africa 179
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 15
AN - Antartide 1
Totale 35.987
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.712
IT - Italia 4.555
SG - Singapore 3.091
CN - Cina 2.746
BR - Brasile 1.591
UA - Ucraina 1.479
HK - Hong Kong 1.169
DE - Germania 1.155
FI - Finlandia 561
VN - Vietnam 523
GB - Regno Unito 501
RU - Federazione Russa 415
TR - Turchia 370
IE - Irlanda 368
FR - Francia 340
PL - Polonia 199
IN - India 193
CA - Canada 145
SE - Svezia 134
BD - Bangladesh 120
NL - Olanda 113
AR - Argentina 107
MX - Messico 86
ZA - Sudafrica 73
ES - Italia 72
IQ - Iraq 69
AT - Austria 64
JP - Giappone 58
BE - Belgio 48
ID - Indonesia 45
EC - Ecuador 43
PK - Pakistan 41
VE - Venezuela 32
MA - Marocco 28
SA - Arabia Saudita 28
CZ - Repubblica Ceca 27
EG - Egitto 25
LT - Lituania 25
CO - Colombia 24
EE - Estonia 24
JO - Giordania 23
AE - Emirati Arabi Uniti 22
UZ - Uzbekistan 21
PY - Paraguay 20
RO - Romania 20
AU - Australia 19
CH - Svizzera 18
CL - Cile 18
AZ - Azerbaigian 17
IL - Israele 15
KE - Kenya 15
UY - Uruguay 15
EU - Europa 14
HR - Croazia 14
KZ - Kazakistan 14
PE - Perù 13
GR - Grecia 12
IR - Iran 12
NP - Nepal 12
PT - Portogallo 12
SK - Slovacchia (Repubblica Slovacca) 12
MK - Macedonia 11
AL - Albania 10
LU - Lussemburgo 10
CR - Costa Rica 9
JM - Giamaica 9
BG - Bulgaria 8
DZ - Algeria 8
KG - Kirghizistan 8
PA - Panama 8
TN - Tunisia 8
LB - Libano 7
PH - Filippine 7
TT - Trinidad e Tobago 7
CI - Costa d'Avorio 6
HN - Honduras 6
AM - Armenia 5
BA - Bosnia-Erzegovina 5
BH - Bahrain 5
LV - Lettonia 5
NI - Nicaragua 5
NO - Norvegia 5
RS - Serbia 5
TH - Thailandia 5
UG - Uganda 5
BO - Bolivia 4
BY - Bielorussia 4
CY - Cipro 4
DO - Repubblica Dominicana 4
GE - Georgia 4
KR - Corea 4
PS - Palestinian Territory 4
DK - Danimarca 3
LI - Liechtenstein 3
MD - Moldavia 3
MU - Mauritius 3
NZ - Nuova Zelanda 3
SI - Slovenia 3
SV - El Salvador 3
AO - Angola 2
Totale 35.955
Salva come PNG Salva come JPEG
Città #
Fairfield 1.572
Singapore 1.370
Ashburn 1.220
Hong Kong 1.167
Woodbridge 1.143
Jacksonville 1.090
Houston 827
Beijing 738
Cambridge 625
Seattle 600
Ann Arbor 587
Wilmington 577
Princeton 549
Chandler 477
New York 412
Los Angeles 399
Milan 364
Nanjing 351
Helsinki 326
Istanbul 300
Dublin 299
Chicago 246
Dallas 237
Munich 226
Brescia 216
Rome 212
Ho Chi Minh City 185
The Dalles 179
Warsaw 177
Buffalo 156
Moscow 152
São Paulo 135
Des Moines 127
Redondo Beach 127
Nanchang 122
San Diego 113
Hanoi 112
San Francisco 111
Florence 110
Hebei 105
Shenyang 105
Changsha 94
Shanghai 93
Salt Lake City 86
Tianjin 86
London 83
Turku 74
Jinan 72
Turin 69
Verona 65
Jiaxing 63
Lancaster 58
Trieste 58
Nuremberg 55
Rio de Janeiro 55
Brooklyn 54
Tokyo 53
Hangzhou 52
Santa Clara 51
Bologna 50
Phoenix 46
Bergamo 45
Brussels 44
Johannesburg 43
Dearborn 42
Atlanta 41
Montreal 41
Chennai 40
Toronto 40
Guangzhou 39
Genoa 38
Belo Horizonte 37
Elk Grove Village 37
Denver 35
Tampa 35
Udine 34
Kunming 33
Ningbo 33
Romola 33
Vienna 33
Padova 32
Stockholm 32
Zhengzhou 30
Lappeenranta 29
Mumbai 28
Poplar 26
Dhaka 25
Lanzhou 25
Mexico City 25
Boardman 24
Falkenstein 24
Frankfurt am Main 24
Genova 24
Pisa 24
Salvador 24
Tallinn 24
Curitiba 23
Orem 23
Paris 23
Taizhou 23
Totale 20.698
Salva come PNG Salva come JPEG
Nome #
ANTICORPI ANTI-TH/TO NELLA SCLEROSI SISTEMICA (SSC): CORRELAZIONI CLINICHE E IMMUNOLOGICHE 2.330
ANTICORPI ANTI-RNA POLIMERASI III: UN MARKER DI ESORDIO PRECOCE DI SCLEROSI SISTEMICA 1.758
Frequency Evaluation of the Interleukin-6 −174G>C Polymorphism and Homeostatic Iron Regulator (HFE) Mutations as Disease Modifiers in Patients Affected by Systemic Lupus Erythematosus and Rheumatoid Arthritis 683
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 395
Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement: a predictive marker for erosive disease? 198
Anti-RNA polymerase III antibodies as a risk marker for early Gastric Antral Vascular Ectasia (GAVE) in systemic sclerosis 192
Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI 184
Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study 184
Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2): Planted Antigens. 183
Anti-RNA polymerase III antibodies: A marker of systemic sclerosis with rapid onset and skin thickening progression 182
COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study 174
Anti-argonaute2 (Ago2/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS). 167
Prevalence and disease-specific risk factors for Lower Urinary Tract symptoms in Systemic Sclerosis: an international multi-centric study 167
First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry) 167
Macrophage activation syndrome in adult systemic lupus erythematosus: Report of seven adult cases from a single Italian rheumatology center 165
Endothelial Dysfunction In Early Systemic Lupus Erythematosus Patients And Controls Without Previous Cardiovascular Events. 163
Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies 163
C9orf72 Intermediate Alleles in Patients with Amyotrophic Lateral Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis 161
Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls: Are there any differences? 158
Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. 154
Antiphospholipid antibodies mediate autoimmunity against dying cells. 154
Endothelial dysfunction in early systemic lupus erythematosus patients and controls without previous cardiovascular events 153
Systemic lupus erythematosus and endothelial dysfunction: A close relationship 153
Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus. 153
Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab 152
Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years 151
Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. 151
Autoimmune polyendocrine Syndromes 149
Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality 149
The clinico-serological spectrum of overlap myositis 149
Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group 148
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy 148
Longterm outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study 147
The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study 146
Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures 144
Endothelial Dysfunction In Early Systemic Lupus Erythematosus Patients And Controls Without Previous Cardiovascular Events 143
Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome 143
Treatment and functional outcome of patients with cystoid macular edema: a single-center experience 142
Discordance for systemic lupus erythematosus and hyper IgE syndrome in a pair of monozygotic twins 142
Antinuclear antibodies in Frontotemporal Dementia: the tip's of autoimmunity iceberg? 141
Antiphospholipid syndrome and glomerular thrombosis in the absence of overt lupus nephritis 140
Relationship between endothelial dysfunction, videocapillaroscopy and circulating CD3+CD31+CXCR4+ lymphocytes in systemic lupus erythematosus without cardiovascular risk factors 139
Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept 139
Aortic stiffness and left ventricular hypertrophy in rheumatoid arthritis: Comment on the article by Rudominer et al. 137
Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. 132
Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera 131
[Neonatal lupus: clinical features and risk of congenital cardiac heart block in newborns from mothers with anti Ro/SSA antibodies] 131
Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. 129
Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis 129
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome 128
Rare autoantibodies to cellular antigens in systemic lupus erythematosus. 127
The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies. 127
Autoantibodies to survival of motor neuron complex in patients with polymyositis: Immunoprecipitation of D, E, F, and G proteins without other components of small nuclear ribonucleoproteins 127
Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: The positive experience of a national multicentre study 127
Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosus. 126
Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women 126
Severe skin involvement in type II cryoglobulinemia successfully treated with thalidomide 125
Anti-Ro/SSA and La/SSB antibodies 124
Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase 123
Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus 122
The 2016 classification criteria for primary Sjogren's syndrome: What's new? 121
Incidence of antiperinuclear factor in patients with psoriatic arthritis. 120
Anti-topoisomerase-I antibodies in systemic lupus erythematosus and potential association with the presence of anti-dsDNA antibodies 119
Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients 119
METODICHE AUTOMATIZZATE PER ANTICORPI ANTINUCLEO (ANA): E' POSSIBILE SOSTITUIRE L'IMMUNOFLUORESCENZA INDIRETTA? 118
Myositis autoantibodies and clinical phenotypes 118
The role of clinically significant antiphospholipid antibodies in systemic lupus erythematosus 118
Chilblain lupus erythematosus is associated with antibodies to SSA/Ro. 117
DECREASED TITER OF ANTI-CCP ANTIBODIES AND RHEUMATOID FACTOR AND REDUCTION OF POSTSWITCH MEMORY B CELLS AFTER ABATACEPT TREATMENT FOR RHEUMATOID ARTHRITIS 117
Multi-antibody composition in lupus nephritis: isotype and antigen specificity make the difference 117
Pathogenetic associations of maternal anti-Ro/SSA antibodies. 116
Belimumab decreases flare rate and hinders the expected damage progression in patients with active systemic lupus erythematosus 116
Celiac Disease Prevalence is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study 116
Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis 116
Antiperinuclear factor in psoriatic arthropathy 115
Primary biliary cirrhosis-related autoantibodies in a large cohort of italian patients with systemic sclerosis 114
Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. 114
Prognostic value of diastolic dysfunction in asymptomatic rheumatoid arthritis patients without cardiovascular risk factors 114
Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study 113
In vivo reflectance confocal microscopy features of cutaneous microcirculation and epidermal and dermal changes in diffuse systemic sclerosis and correlation with histological and videocapillaroscopic findings. 113
Elastic properties of the ascending aorta in patients with rheumatoid arthritis. 112
75-SeHCAT retention test in chronic cholestatic disease: comparison with health and effect of bile acid therapy. 112
International cohort study of 73 anti-Ku-positive patients: Association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis 112
Update on Antiphospholipid Syndrome: Ten Topics in 2017 112
Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. 111
Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. 111
The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus 111
Determination of antibodies to extractable nuclear antigens by commercial kits: a multicenter study 111
Serum prealbumin is an independent predictor of mortality in systemic sclerosis outpatients 110
Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies. 109
Evaluation of a novel particle-based assay for detection of autoantibodies in idiopathic inflammatory myopathies. 109
Analysis of C9Orf72 Expansions in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Data 109
Systematic Review and Meta-analysis on the Association of Occupational Exposure to Free Crystalline Silica and Rheumatoid Arthritis 109
Deforming arthropathy of the hands in Systemic Lupus Erythematosus is associated with antibodies to SS-A/Ro and to SS-B/La. 108
Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. 108
Cardiological features in idiopathic inflammatory myopathies. 108
A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies. 108
A prospective evaluation of endothelial dysfunction in systemic Lupus Erythematosus patients without previous cardiovascular events: preliminary results 108
A prospective evaluation of endothelial dysfunction in Systemic Lupus Erythematosus patients without previous cardiovascular events: preliminary results. 108
Serologic profile and mortality rates of scleroderma renal crisis in Italy 107
Totale 17.999
Salva come PNG Salva come JPEG
Categoria #
all - tutte 179.883
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 179.883
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.629 0 0 0 0 0 467 156 446 466 472 395 227
2021/20223.010 185 401 140 176 164 200 201 234 193 296 272 548
2022/20232.266 341 38 51 99 194 564 47 229 384 56 139 124
2023/20242.853 150 84 228 246 134 458 134 138 667 94 107 413
2024/20257.324 117 156 125 734 678 592 568 343 675 585 1.492 1.259
2025/20267.516 1.224 1.862 1.068 1.878 1.336 148 0 0 0 0 0 0
Totale 36.500